Top of this page
Skip navigation, go straight to the content

Investors Overview

we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 

2018 FY results

Business general picture


IR events

DateEvent details
19 June
Citi 8th Annual European Healthcare Conference, London1/1 meetings
20 June
J.P. Morgan European Healthcare Conference 2019, London1/1 meetings
25 July
2019 half-year resultsMore details closer to the date

Outlook 2019

2019 revenue reporting to reach approximately

€ 4.6-4.7 billion 

Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] in the range of

27-29% of revenue 

Core earnings per share are therefore expected in the range of

€ 4.40-4.80

based on an average of
188 million shares outstanding

Contact UCB IR team or a specific team member:




UCB IR app available on Apple Store

UCB IR app available on Google Play